Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
08 nov. 2024 14h51 HE
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presents data on IRX5010 showing inhibition of tumor infiltrating T-cells and myeloid derived suppressor cells in multiple cancers
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Gene Vector Therapy, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
08 nov. 2024 06h00 HE
|
GenVivo, Inc.
GEN2 was studied in patients with hepatocellular carcinoma or advanced solid tumors metastatic to the liver and was well-tolerated at all dose levels administered21% of patients remained on study for...
SynOx Therapeutics Further Strengthens Executive Team with Appointments of U.S.-Based Chief Medical Officer and Chief Commercial Officer
07 nov. 2024 07h00 HE
|
SynOx Therapeutics Limited
Additions of Elyse Seltzer, M.D., as CMO and Robert Francomano as CCO Strengthen Company’s Presence in the U.S. Seasoned Team to Drive Forward Pivotal Phase 3 Trial of Emactuzumab in Patients...
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
06 nov. 2024 16h45 HE
|
OncoCyte Corporation
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
06 nov. 2024 16h02 HE
|
Revolution Medicines, Inc.
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a...
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
06 nov. 2024 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...
Sonrai Accelerates Cancer Therapeutics Research with Advanced Analytics
06 nov. 2024 09h00 HE
|
Sonrai Analytics Ltd
BELFAST, Northern Ireland, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonrai Analytics (Sonrai), an AI precision medicine company providing advanced analytics to advance therapeutic development, is working...
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
06 nov. 2024 07h30 HE
|
Plus Therapeutics Inc.; Spectron RX
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Immunocore reports third quarter financial results and provides a business update
06 nov. 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in...
Press Release Biocartis NV: Biocartis appoints Randy Polonsky as Chief Financial Officer
05 nov. 2024 12h20 HE
|
Biocartis NV
PRESS RELEASE - 05/11/2024, 18:15 CET Biocartis appoints Randy Polonsky as Chief Financial Officer Mechelen, Belgium, 05 November 2024 – Biocartis NV (“Biocartis”), an innovative molecular...